Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P04637: Variant p.Gln354Lys

Cellular tumor antigen p53
Gene: TP53
Feedback?
Variant information Variant position: help 354 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glutamine (Q) to Lysine (K) at position 354 (Q354K, p.Gln354Lys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (Q) to large size and basic (K) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In a sporadic cancer; somatic mutation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 354 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 393 The length of the canonical sequence.
Location on the sequence: help GRERFEMFRELNEALELKDA Q AGKEPGGSRAHSSHLKSKKG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         GRERFEMFRELNEALELKDAQAGKEPGGSRAH---SSHLKSKKG

                              GRERYEMFRNLNEALELKDAQSGKEPGGSRAH---SSHLKA

Rhesus macaque                GRERFEMFRELNEALELKDAQAGKEPAGSRAH---SSHLKS

Mouse                         GRKRFEMFRELNEALELKDAHATEESGDSRAH---SSYLKT

Rat                           GRERFEMFRELNEALELKDARAAEESGDSRAH---SSYPKT

Pig                           GRERFEMFRELNDALELKDAQTARESGENRAH---SSHLKS

Bovine                        GFKRYEMFRELNDALELKDALDGREPGESRAH---SSHLKS

Rabbit                        GRERFEMFRELNEALELKDAQAEKEPGGSRAH---SSYLKA

Sheep                         GRKRFEMFRELNEALELMDAQAGREPGESRAH---SSHLKS

Cat                           GRERFEMFRELNEALELKDAQSGKEPGGSRAH---SSHLKA

Chicken                       GRRRYEMLKEINEALQLAEGGSAPRPS--------KGRRVK

Xenopus laevis                GRSRYEMIKKLNDALELQESLDQQKVT--------IKCRKC

Zebrafish                     GRERYEILKKLNDSLELSDVVPASDAEKYRQKFMTKNKKEN

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 393 Cellular tumor antigen p53
Region 100 – 370 Interaction with HIPK1
Region 300 – 393 Interaction with CARM1
Region 319 – 360 Interaction with HIPK2
Region 325 – 356 Oligomerization
Region 351 – 393 Disordered
Modified residue 335 – 335 Symmetric dimethylarginine; by PRMT5
Modified residue 337 – 337 Symmetric dimethylarginine; by PRMT5
Modified residue 370 – 370 N6,N6-dimethyllysine; alternate
Modified residue 370 – 370 N6-methyllysine; by SMYD2; alternate
Modified residue 372 – 372 N6-methyllysine; by SETD7
Modified residue 373 – 373 N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate
Modified residue 373 – 373 N6-acetyllysine; alternate
Alternative sequence 342 – 393 Missing. In isoform 2, isoform 5 and isoform 8.
Alternative sequence 347 – 393 Missing. In isoform 3, isoform 6 and isoform 9.
Mutagenesis 359 – 359 P -> D. Abolishes binding to USP7.
Mutagenesis 361 – 361 G -> E. Abolishes binding to USP7.
Mutagenesis 362 – 362 S -> A. Abolishes binding to USP7.
Mutagenesis 370 – 370 K -> R. Induces a decrease in methylation by SMYD2.
Mutagenesis 372 – 372 K -> R. Induces a decrease in protein stabilization.
Mutagenesis 373 – 373 K -> R. Abolishes dimethylation by EHMT1 and EHMT2.
Helix 335 – 354



Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.